Nationwide multicenter observational study of FOLFIRINOX chemotherapy in 399 patients with unresectable or recurrent pancreatic cancer in Japan
A Todaka, N Mizuno, M Ozaka, H Ueno, S Kobayashi… - Pancreas, 2018 - journals.lww.com
Objectives FOLFIRINOX (oxaliplatin, irinotecan, 5-fluorouracil, and leucovorin) is the
standard therapy worldwide for unresectable pancreatic cancer; however, clinical data for …
standard therapy worldwide for unresectable pancreatic cancer; however, clinical data for …
Real-world dose reduction of standard and modified FOLFIRINOX in metastatic pancreatic cancer: a systematic review, evidence-mapping, and meta-analysis
K Jung, S Choi, H Song, K Kwak… - Therapeutic …, 2023 - journals.sagepub.com
Background: FOLFIRINOX, used in metastatic pancreatic cancer (MPC), is highly efficacious
but also toxic. Various dose modifications for FOLFIRINOX have been introduced to reduce …
but also toxic. Various dose modifications for FOLFIRINOX have been introduced to reduce …
Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer
T Mie, T Sasaki, T Okamoto, T Takeda… - Japanese Journal of …, 2022 - academic.oup.com
Background To compare the treatment outcomes of nanoliposomal-irinotecan (nal-IRI) plus
fluorouracil and leucovorin (5-FU/LV) and modified FOLFIRINOX (mFFX) as second-line …
fluorouracil and leucovorin (5-FU/LV) and modified FOLFIRINOX (mFFX) as second-line …
A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic …
K Saito, H Isayama, Y Sakamoto, Y Nakai, K Ishigaki… - Medical Oncology, 2018 - Springer
There has been a pressing need to develop optimal regimen for neoadjuvant chemotherapy
(NAC) for pancreatic cancer (PC). The safety and efficacy of gemcitabine, S-1, and LV …
(NAC) for pancreatic cancer (PC). The safety and efficacy of gemcitabine, S-1, and LV …
Safety and Efficacy Analysis of PD-1 Inhibitors in Combination with Gemcitabine Plus Nab-Paclitaxel for Advanced Pancreatic Cancer: A Real-World, Single-Center …
Z Chen, Y He, C Ding, J Chen, Y Gu… - OncoTargets and …, 2023 - Taylor & Francis
Background Pancreatic cancer is a deadly disease with a low five years survival rate, and
chemotherapy remains the standard treatment for advanced cases. However, the efficacy of …
chemotherapy remains the standard treatment for advanced cases. However, the efficacy of …
Management of elderly patients with unresectable pancreatic cancer
S Kobayashi, M Ueno, H Ishii… - Japanese Journal of …, 2022 - academic.oup.com
Systemic chemotherapy plays important role in pancreatic cancer not only for palliative
treatment of unresectable disease, but also for neoadjuvant and adjuvant treatment of …
treatment of unresectable disease, but also for neoadjuvant and adjuvant treatment of …
Chemotherapy-induced neutropenia as a prognostic factor in patients with pancreatic cancer treated with gemcitabine plus nab-paclitaxel: a retrospective cohort study
M Kan, H Imaoka, K Watanabe, M Sasaki… - Cancer Chemotherapy …, 2020 - Springer
Objectives Chemotherapy-induced neutropenia (CIN) is a common adverse event of
chemotherapy. Several reports have suggested that CIN could be an important prognostic …
chemotherapy. Several reports have suggested that CIN could be an important prognostic …
Platinum-Based chemotherapy in locally advanced or metastatic pancreatic ductal adenocarcinoma: Summary of evidence and application in clinical practice
A Reinacher-Schick, D Arnold, M Venerito… - Oncology Research …, 2022 - karger.com
Background: Different therapeutic options are available for the treatment of advanced or
metastatic pancreatic ductal adenocarcinoma (PDAC). Platinum-based multi-agent …
metastatic pancreatic ductal adenocarcinoma (PDAC). Platinum-based multi-agent …
[HTML][HTML] Feasibility of alternating induction and maintenance chemotherapy in pancreatic cancer
A Hann, W Bohle, J Egger, W Zoller - Scientific Reports, 2017 - nature.com
Chemotherapy regimens for pancreatic ductal adenocarcinoma (PDAC) have changed
since the introduction of FOLFIRINOX. Due to toxicity, dosage and number of applied cycles …
since the introduction of FOLFIRINOX. Due to toxicity, dosage and number of applied cycles …
Treatment patterns and cost estimations of systemic chemotherapy for pancreatic cancer in Japan: A retrospective database study
Y Takumoto, R Shibahara, H Asami… - Cancer …, 2023 - Wiley Online Library
Background This study aimed to clarify the treatment patterns of pancreatic cancer patients
receiving systemic chemotherapy in Japan and to estimate the direct medical costs in actual …
receiving systemic chemotherapy in Japan and to estimate the direct medical costs in actual …